Biomarker & Intervention Discovery

Atrial Fibrillation

This page lists 9 druggable gene targets, 40 approved or trial-tested drug candidates and 15 recent clinical trials for Atrial Fibrillation, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs3.13MWHO GHE 2021 · all ages
Global DALYs28.29MWHO GHE 2021 · worldwide
US mortality109.5K deaths/yrWHO GHE 2021
Global mortality1.02M deaths/yrWHO GHE 2021 · worldwide
NIH funding$1.78BFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionSpontaneous reversion to sinus rhythm occurs in ~50% of paroxysmal AF within 24-48 hours; persistent AF almost never…
Best-intervention remissionCatheter ablation achieves freedom from AF in ~70-80% at 1 year (paroxysmal), 50-60% (persistent); ablation superior…
Gap sizeLarge — rate control vs rhythm control debate has shifted but practice hasn't caught up
Primary barrierpractice
Full remission profile →

Remission & chronicity

Spontaneous remission
Spontaneous reversion to sinus rhythm occurs in ~50% of paroxysmal AF within 24-48 hours; persistent AF almost never self-terminates; rate-control (the dominant strategy) by definition keeps the patient in AF
Best-intervention remission
Catheter ablation achieves freedom from AF in ~70-80% at 1 year (paroxysmal), 50-60% (persistent); ablation superior to antiarrhythmic drugs (52% vs 71% AF recurrence, CABANA trial); EAST-AFNET 4 showed early rhythm control reduced major adverse CV events vs rate control
Gap size
Large — rate control vs rhythm control debate has shifted but practice hasn't caught up
Primary barrier
practice
Guidelines now support earlier rhythm control and ablation, but rate control with lifelong anticoagulation remains the dominant practice pattern; AF management is described as 'moving ahead of established guidelines' per ESC 2023

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ADRB1 288AGTR1 249GJA1 23KCNA5 208KCNH2 508KCNQ1 72RYR2 68SCN5A 288TGFB1 62
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BRETYLIUM ? unclear Mechanistic
PINDOLOL ↑ activates Mechanistic
BISOPROLOL ? unclear Mechanistic
FLECAINIDE ACETATE ? unclear Mechanistic
METIPRANOLOL ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
ATENOLOL ↓ inhibits Mechanistic
BUCINDOLOL HYDROCHLORIDE ↓ inhibits Mechanistic
METIPRANOLOL HYDROCHLORIDE ↓ inhibits Mechanistic
ALPRENOLOL ? unclear Mechanistic 4.88 nM (IC50)
PRACTOLOL ↓ inhibits Mechanistic
XAMOTEROL ↑ activates Mechanistic
PENBUTOLOL ? unclear Mechanistic
DOBUTAMINE ? unclear Mechanistic
BETHANIDINE ? unclear Mechanistic
BETAXOLOL ? unclear Mechanistic 37.1 nM (IC50)
MURAGLITAZAR ? unclear Mechanistic
ACEBUTOLOL ? unclear Mechanistic
LABETALOL HYDROCHLORIDE ↓ inhibits Mechanistic
ACEBUTOLOL HYDROCHLORIDE ↓ inhibits Mechanistic
NOREPINEPHRINE ? unclear Mechanistic
OT-730 ? unclear Mechanistic
CARVEDILOL ↓ inhibits Mechanistic
NADOLOL ↓ inhibits Mechanistic
LEVOBUNOLOL ↓ inhibits Mechanistic
LABETALOL ? unclear Mechanistic
TERTATOLOL ? unclear Mechanistic
ARBUTAMINE ? unclear Mechanistic
PROPRANOLOL HYDROCHLORIDE ↓ inhibits Mechanistic
ZIPRASIDONE ? unclear Mechanistic
BUPRANOLOL ? unclear Mechanistic
LANDIOLOL ↓ inhibits Mechanistic
OXPRENOLOL ? unclear Mechanistic
MEPINDOLOL ? unclear Mechanistic
CELIPROLOL ↓ inhibits Mechanistic
BISOPROLOL FUMARATE ↓ inhibits Mechanistic
DESIPRAMINE ? unclear Mechanistic
DOPAMINE ↑ activates Mechanistic
ISOPROTERENOL ↑ activates Mechanistic
DOBUTAMINE HYDROCHLORIDE ↑ activates Mechanistic

Showing top 40 of 288 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CANDESARTAN CILEXETIL ↓ inhibits Mechanistic
CHEMBL:CHEMBL586135 ? unclear Mechanistic
VALSARTAN ↓ inhibits Mechanistic 4700.0 nM (Ki)
EPROSARTAN MESYLATE ↓ inhibits Mechanistic
FIMASARTAN ↓ inhibits Mechanistic
ASCORBIC ACID ? unclear Mechanistic
OLMESARTAN MEDOXOMIL ↓ inhibits Mechanistic
AZILSARTAN MEDOXOMIL ↓ inhibits Mechanistic
THERAPEUTIC ANDROSTANOLONE ? unclear Mechanistic
CHEMBL:CHEMBL347610 ? unclear Mechanistic
CHEMBL:CHEMBL421088 ? unclear Mechanistic
LOSARTAN POTASSIUM ↓ inhibits Mechanistic 5.5 nM (IC50)
CHEMBL:CHEMBL1492017 ? unclear Mechanistic
SPARSENTAN ↓ inhibits Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL261693 ? unclear Mechanistic
CHEMBL:CHEMBL1972216 ? unclear Mechanistic
EPROSARTAN ? unclear Mechanistic 7.3 nM (IC50)
C-FOS ANTISENSE ? unclear Mechanistic
SARALASIN ACETATE ↓ inhibits Mechanistic
IRBESARTAN ↓ inhibits Mechanistic 1.1 nM (Ki)
DISULFIRAM ? unclear Mechanistic
SAPRISARTAN ? unclear Mechanistic
H2O2 ? unclear Mechanistic
CHEMBL:CHEMBL591834 ? unclear Mechanistic
CAPTOPRIL ? unclear Mechanistic
ANGIOTENSIN II ? unclear Mechanistic
CHEMBL:CHEMBL400912 ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
IDOXIFENE ? unclear Mechanistic
CHEMBL:CHEMBL528694 ? unclear Mechanistic
IL-6 ? unclear Mechanistic
ANGIOTENSIN II ACETATE ↑ activates Mechanistic
LEVODOPA ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
AZILSARTAN KAMEDOXOMIL ↓ inhibits Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
CHEMBL:CHEMBL1445650 ? unclear Mechanistic
MUSCLE RELAXANT ? unclear Mechanistic
CL-329167 ? unclear Mechanistic

Showing top 40 of 249 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
SELENIUM ? unclear Mechanistic
CARVEDILOL ? unclear Mechanistic
PROPYLTHIOURACIL ? unclear Mechanistic
BLEOMYCIN ? unclear Mechanistic
VITAMIN A ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
PROTEASOME INHIBITOR ? unclear Mechanistic
LABETALOL ? unclear Mechanistic
PROTEASE INHIBITOR ? unclear Mechanistic
ASCORBIC ACID ? unclear Mechanistic
EPIGALLOCATECHIN GALLATE ? unclear Mechanistic
CHEMBL4793190 ↓ inhibits Mechanistic 4100.0 nM (IC50)
CHEMBL4794431 ↓ inhibits Mechanistic 3100.0 nM (IC50)
CHEMBL4777167 ↓ inhibits Mechanistic 17100.0 nM (IC50)
CHEMBL4777222 ↓ inhibits Mechanistic 26600.0 nM (IC50)
CHEMBL4784426 ↓ inhibits Mechanistic 6200.0 nM (IC50)
CHEMBL4778380 ↓ inhibits Mechanistic 5500.0 nM (IC50)
CHEMBL4790312 ↓ inhibits Mechanistic 6200.0 nM (IC50)
CHEMBL4776897 ↓ inhibits Mechanistic 8900.0 nM (IC50)
CHEMBL4780949 ↓ inhibits Mechanistic 17700.0 nM (IC50)
CHEMBL4785499 ↓ inhibits Mechanistic 8900.0 nM (IC50)
CHEMBL4799209 ↓ inhibits Mechanistic 8600.0 nM (IC50)
KANAMYCIN ↓ inhibits Mechanistic 48000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DALFAMPRIDINE ↓ inhibits Mechanistic
T-226296 ? unclear Mechanistic
TEDISAMIL ↓ inhibits Mechanistic
AMIFAMPRIDINE PHOSPHATE ↓ inhibits Mechanistic
DRONEDARONE ? unclear Mechanistic
GUANIDINE HYDROCHLORIDE ↓ inhibits Mechanistic
LORATADINE ? unclear Mechanistic
BMS-394136 ? unclear Mechanistic
VERNAKALANT HYDROCHLORIDE ↓ inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
BMS-919373 ? unclear Mechanistic
DIHYDROTESTOSTERONE ? unclear Mechanistic
AMIFAMPRIDINE ↓ inhibits Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
TERFENADINE ? unclear Mechanistic
VERNAKALANT ? unclear Mechanistic
CHEMBL314328 ↓ inhibits Mechanistic 6700.0 nM (IC50)
SERTINDOLE ↓ inhibits Mechanistic 2000.0 nM (IC50)
CHEMBL97793 ↓ inhibits Mechanistic 10000.0 nM (IC50)
CHEMBL97646 ↓ inhibits Mechanistic 3200.0 nM (IC50)
CHEMBL316891 ↓ inhibits Mechanistic 6900.0 nM (IC50)
CHEMBL327334 ↓ inhibits Mechanistic 3800.0 nM (IC50)
CHEMBL288131 ↓ inhibits Mechanistic 100.0 nM (IC50)
CHEMBL433220 ↓ inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL328905 ↓ inhibits Mechanistic 5000.0 nM (IC50)
CHEMBL318879 ↓ inhibits Mechanistic 500.0 nM (IC50)
CHEMBL95368 ↓ inhibits Mechanistic 700.0 nM (IC50)
CHEMBL94826 ↓ inhibits Mechanistic 3500.0 nM (IC50)
CHEMBL418972 ↓ inhibits Mechanistic 6500.0 nM (IC50)
CHEMBL97682 ↓ inhibits Mechanistic 5600.0 nM (IC50)
CHEMBL97828 ↓ inhibits Mechanistic 3100.0 nM (IC50)
CHEMBL319775 ↓ inhibits Mechanistic 1600.0 nM (IC50)
CHEMBL316494 ↓ inhibits Mechanistic 2200.0 nM (IC50)
CHEMBL98077 ↓ inhibits Mechanistic 8500.0 nM (IC50)
CHEMBL327816 ↓ inhibits Mechanistic 600.0 nM (IC50)
CHEMBL319310 ↓ inhibits Mechanistic 500.0 nM (IC50)
CHEMBL273418 ↓ inhibits Mechanistic 600.0 nM (IC50)
CHEMBL420266 ↓ inhibits Mechanistic 6200.0 nM (IC50)
CHEMBL289939 ↓ inhibits Mechanistic 200.0 nM (IC50)
CHEMBL94764 ↓ inhibits Mechanistic 4100.0 nM (IC50)

Showing top 40 of 208 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLARITHROMYCIN ? unclear Mechanistic
PYRILAMINE MALEATE ? unclear Mechanistic
CHEMBL:CHEMBL525106 ? unclear Mechanistic
CHEMBL:CHEMBL584829 ? unclear Mechanistic
TAMOXIFEN CITRATE ? unclear Mechanistic
CHEMBL:CHEMBL529640 ? unclear Mechanistic
SPIPERONE HYDROCHLORIDE ? unclear Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
CHEMBL:CHEMBL1437888 ? unclear Mechanistic
CHEMBL:CHEMBL602312 ? unclear Mechanistic
CHEMBL:CHEMBL49055 ? unclear Mechanistic
NISOXETINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL591887 ? unclear Mechanistic
SOTALOL ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
CHEMBL:CHEMBL601492 ? unclear Mechanistic
CHEMBL:CHEMBL1256726 ? unclear Mechanistic
N-AMINOHEXYL-5-CHLORO-1-NAPTHALENESULFONAMIDE HYDROCHLORIDE ? unclear Mechanistic
KEPONE ? unclear Mechanistic
PHENOXYBENZAMINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL592344 ? unclear Mechanistic
CHEMBL:CHEMBL582486 ? unclear Mechanistic
CHEMBL:CHEMBL589946 ? unclear Mechanistic
PERPHENAZINE ? unclear Mechanistic
CHEMBL:CHEMBL601528 ? unclear Mechanistic
CHEMBL:CHEMBL545880 ? unclear Mechanistic
GR 89696 ? unclear Mechanistic
PD-169316 ? unclear Mechanistic
IOFETAMINE HYDROCHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL601325 ? unclear Mechanistic
BISOPROLOL ? unclear Mechanistic
ROPINIROLE HYDROCHLORIDE ? unclear Mechanistic
DROPERIDOL ? unclear Mechanistic 32.2 nM (IC50)
CHEMBL:CHEMBL534084 ? unclear Mechanistic
OLEIC ACID ? unclear Mechanistic
L-741,626 ? unclear Mechanistic
CHEMBL:CHEMBL602580 ? unclear Mechanistic
CHEMBL:CHEMBL580516 ? unclear Mechanistic
VINPOCETINE ? unclear Mechanistic
CHEMBL:CHEMBL547488 ? unclear Mechanistic

Showing top 40 of 508 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
EXENATIDE ? unclear Mechanistic
NIFLUMIC ACID ↑ activates Mechanistic
EZOGABINE ↑ activates Mechanistic
DOLASETRON ? unclear Mechanistic
GUANIDINE HYDROCHLORIDE ↓ inhibits Mechanistic
IKS124 ↓ inhibits Mechanistic
INDOMETHACIN ? unclear Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
PYRITHIONE ZINC ↑ activates Mechanistic
SITAGLIPTIN ? unclear Mechanistic
FLUOROURACIL ? unclear Mechanistic
INDAPAMIDE ? unclear Mechanistic
MEFENAMIC ACID ↑ activates Mechanistic
TEDISAMIL ↓ inhibits Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
XE991 ↓ inhibits Mechanistic
ANHYDROUS TACROLIMUS ? unclear Mechanistic
BEPRIDIL ? unclear Mechanistic
HMR-1556 ↓ inhibits Mechanistic
AMIFAMPRIDINE PHOSPHATE ↓ inhibits Mechanistic
(3R,4S)-293B ↓ inhibits Mechanistic
L735821 ↓ inhibits Mechanistic
DALFAMPRIDINE ↓ inhibits Mechanistic
JNJ303 ↓ inhibits Mechanistic
CELECOXIB ? unclear Mechanistic
AMIFAMPRIDINE ↓ inhibits Mechanistic
EPIRUBICIN ? unclear Mechanistic
3S,4R-293B ↓ inhibits Mechanistic
REPAGLINIDE ? unclear Mechanistic
VILDAGLIPTIN ? unclear Mechanistic
R-L3 ↑ activates Mechanistic
ML277 ↑ activates Mechanistic
ICA-105665 ? unclear Mechanistic
OXALIPLATIN ? unclear Mechanistic
VOLINANSERIN ↓ inhibits Mechanistic 1060.0 nM (Ki)
CHEMBL1689654 ↑ activates Mechanistic 49290.0 nM (EC50)
CHEMBL1352968 ↑ activates Mechanistic 1690.0 nM (EC50)
CHEMBL2070830 ↑ activates Mechanistic 1470.0 nM (EC50)
CHEMBL2070832 ↑ activates Mechanistic 1380.0 nM (EC50)
CHEMBL2070952 ↑ activates Mechanistic 890.0 nM (EC50)

Showing top 40 of 72 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
RUTHENIUM RED ↓ inhibits Mechanistic
MG2+ ↓ inhibits Mechanistic
CAFFEINE ↑ activates Mechanistic
VK-II-86 ↓ inhibits Mechanistic
RYANODINE ↓ inhibits Mechanistic
SURAMIN ↑ activates Mechanistic
CA2+ ↓ inhibits Mechanistic
ADENOSINE TRIPHOSPHATE ↑ activates Mechanistic
CERIVASTATIN ? unclear Mechanistic
PROCAINE ↓ inhibits Mechanistic
CARVEDILOL ↓ inhibits Mechanistic
CHEMBL3941132 ↑ activates Mechanistic 150.0 nM (EC50)
CHEMBL3932239 ↑ activates Mechanistic 211.0 nM (EC50)
CHEMBL3902651 ↑ activates Mechanistic 102.0 nM (EC50)
CHEMBL3899882 ↑ activates Mechanistic 208.0 nM (EC50)
CHEMBL3961593 ↑ activates Mechanistic 252.0 nM (EC50)
CHEMBL3952083 ↑ activates Mechanistic 55.0 nM (EC50)
CHEMBL3909362 ↑ activates Mechanistic 205.0 nM (EC50)
CHEMBL3906571 ↑ activates Mechanistic 181.0 nM (EC50)
CHEMBL3933756 ↑ activates Mechanistic 197.0 nM (EC50)
CHEMBL3936508 ↑ activates Mechanistic 174.0 nM (EC50)
CHEMBL3895741 ↑ activates Mechanistic 182.0 nM (EC50)
CHEMBL3898439 ↑ activates Mechanistic 265.0 nM (EC50)
CHEMBL3949995 ↑ activates Mechanistic 355.0 nM (EC50)
CHEMBL3902432 ↑ activates Mechanistic 268.0 nM (EC50)
CHEMBL3982028 ↑ activates Mechanistic 40.0 nM (EC50)
CHEMBL3933375 ↑ activates Mechanistic 40.0 nM (EC50)
CHEMBL3928727 ↑ activates Mechanistic 50.0 nM (EC50)
ALADORIAN ↑ activates Mechanistic 15.0 nM (EC50)
CHEMBL3984280 ↑ activates Mechanistic 44.0 nM (EC50)
CHEMBL3932540 ↑ activates Mechanistic 100.0 nM (EC50)
CHEMBL3957737 ↑ activates Mechanistic 80.0 nM (EC50)
CHEMBL3984065 ↑ activates Mechanistic 121.0 nM (EC50)
CHEMBL3893618 ↑ activates Mechanistic 80.0 nM (EC50)
CHEMBL3918890 ↑ activates Mechanistic 150.0 nM (EC50)
CHEMBL3958409 ↑ activates Mechanistic 20.0 nM (EC50)
CHEMBL3953088 ↑ activates Mechanistic 81.0 nM (EC50)
CHEMBL3965149 ↑ activates Mechanistic 40.0 nM (EC50)
CHEMBL3961914 ↑ activates Mechanistic 175.0 nM (EC50)
CHEMBL3925184 ↑ activates Mechanistic 143.0 nM (EC50)

Showing top 40 of 68 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
COCAINE ? unclear Mechanistic
PROCAINAMIDE ? unclear Mechanistic
CHLOROPROCAINE ↓ inhibits Mechanistic
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic
PHENACEMIDE ↓ inhibits Mechanistic
INDECAINIDE HYDROCHLORIDE ↓ inhibits Mechanistic
ETHOTOIN ↓ inhibits Mechanistic
PROPOXYCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
RANOLAZINE ↓ inhibits Mechanistic
MORICIZINE ? unclear Mechanistic
FOSPHENYTOIN ↓ inhibits Mechanistic
QUINIDINE ? unclear Mechanistic 6900.0 nM (IC50)
LIDOCAINE ↓ inhibits Mechanistic
FLECAINIDE ACETATE ↓ inhibits Mechanistic
LIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
PROCAINAMIDE HYDROCHLORIDE ↓ inhibits Mechanistic
QUINIDINE SULFATE ↓ inhibits Mechanistic
HEXYLCAINE ? unclear Mechanistic
LACOSAMIDE ↓ inhibits Mechanistic
NKTR-171 ↓ inhibits Mechanistic
ZONISAMIDE ↓ inhibits Mechanistic
DISOPYRAMIDE ? unclear Mechanistic
PHENYTOIN SODIUM ↓ inhibits Mechanistic
PRENYLAMINE ↓ inhibits Mechanistic
TOCAINIDE ? unclear Mechanistic
AMIODARONE HYDROCHLORIDE ? unclear Mechanistic
QUINIDINE GLUCONATE ↓ inhibits Mechanistic
PRIMIDONE ↓ inhibits Mechanistic
BENZONATATE ? unclear Mechanistic
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic
PROPAFENONE ? unclear Mechanistic 3300.0 nM (IC50)
CENOBAMATE ↓ inhibits Mechanistic
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic
AZD7009 ↓ inhibits Mechanistic
PRILOCAINE ↓ inhibits Mechanistic
TOPIRAMATE ↓ inhibits Mechanistic
LAMOTRIGINE ↓ inhibits Mechanistic 62000.0 nM (IC50)
LOMERIZINE ? unclear Mechanistic
CARBAMAZEPINE ↓ inhibits Mechanistic
DRONEDARONE HYDROCHLORIDE ↓ inhibits Mechanistic

Showing top 40 of 288 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERFERON ALFA-2B ? unclear Mechanistic
PIOGLITAZONE HYDROCHLORIDE ? unclear Mechanistic
SILYMARIN ? unclear Mechanistic
RITUXIMAB ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
PROTEASOME INHIBITOR ? unclear Mechanistic
FRESOLIMUMAB ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
BINTRAFUSP ALFA ~ modulates Mechanistic
NISEVOKITUG ? unclear Mechanistic
LUSPATERCEPT ↓ inhibits Mechanistic
TRETINOIN ? unclear Mechanistic
HYDROCORTISONE BUTYRATE ? unclear Mechanistic
VITAMIN E ? unclear Mechanistic
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic
INOSITOL ? unclear Mechanistic
NICOTINE POLACRILEX ? unclear Mechanistic
FENRETINIDE ? unclear Mechanistic
MELATONIN ? unclear Mechanistic
ISOTRETINOIN ? unclear Mechanistic
VACTOSERTIB ? unclear Mechanistic 12.9 nM (IC50)
TRIAMCINOLONE ? unclear Mechanistic
TAMOXIFEN ? unclear Mechanistic
ADRIAMYCIN ? unclear Mechanistic
HEPARAN SULFATE ? unclear Mechanistic
GOSSYPOL ? unclear Mechanistic
TCDD ? unclear Mechanistic
AMIFOSTINE ANHYDROUS ? unclear Mechanistic
RAMIPRIL ? unclear Mechanistic
ANTIOXIDANT ? unclear Mechanistic
SOTATERCEPT ? unclear Mechanistic
ASPIRIN ? unclear Mechanistic
GALUNISERTIB ? unclear Mechanistic
KEYHOLE LIMPET HEMOCYANIN ? unclear Mechanistic
PIRFENIDONE ? unclear Mechanistic
H2O2 ? unclear Mechanistic
THERAPEUTIC ANDROGEN ? unclear Mechanistic
SANDOSTATIN ? unclear Mechanistic
BROXURIDINE ? unclear Mechanistic
DISITERTIDE ? unclear Mechanistic

Showing top 40 of 62 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Atrial Fibrillation: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT07900685 Phase: N/A Started: 2026-10-19

Pulsed Field Ablation (PFA) has created a 'paradigm shift' within cardiac electrophysiology and the initial experience demonstrates that PFA is safe, rapid and effective compared to both radiofrequency ablation and cryoablation in atrial fibrillation (AF). Presently, AF ablation procedures in the UK...

NCT07217067 Phase: 2 Started: 2025-10-28

A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

NCT07490808 Phase: N/A Started: 2026-03-20

PFA is an emerging non-thermal ablation technology with favorable procedural safety; however, recent studies have raised concerns about peri-procedural hemolysis and subsequent AKI after PFA. This study is a single-center, open-label, randomized controlled trial designed to evaluate whether standard...

NCT07626411 Phase: 3 Started: 2026-08-10

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. The aim of the study is to see how ...

NCT07405671 Phase: 4 Started: 2026-09

The goal of this clinical trial is to learn whether the antiarrhythmic drug flecainide can be used as safely as standard rhythm-control drugs in people with atrial fibrillation (AF) and stable coronary artery disease (CAD). The study includes adults aged 18 years and older who have AF and known but ...

NCT07175428 Phase: 2 Started: 2025-10-20

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillati...

NCT06401616 Phase: 4 Started: 2024-05-21

Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when...

NCT07272902 Phase: N/A Started: 2026-01-01

This study is testing two different ways of treating atrial fibrillation (AF) in people who also have heart failure with mildly reduced or preserved heart function. Patients will randomly be assigned to either rhythm control using catheter ablation or rate control using medicines. The pilot phase wi...

NCT07625215 Phase: 2 Started: 2026-09-01

The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called ele...

NCT03310125 Phase: 3 Started: 2018-02-14

The prevention of perioperative atrial fibrillation (AF) and myocardial injury after non-cardiac surgery (MINS) has the potential to reduce mortality, stroke, and hospital stays in patients undergoing major thoracic surgery. Data from cardiac surgery patients suggest that prevention of perioperative...

CHAMPION-AF Clinical Trial Active Not Recruiting
NCT04394546 Phase: N/A Started: 2020-10-15

The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.

NCT07430956 Phase: 3 Started: 2026-04-03

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can s...

NCT05836987 Phase: 3 Started: 2023-07-13

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in partic...

NCT07424690 Phase: N/A Started: 2026-10-05

ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure. The study compares two ...

NCT06716021 Phase: 3 Started: 2026-08-20

This is a multi-national, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil NS in patients with atrial fibrillation (AF). This study includes Screening Visit, Randomization Visit, a Treatment Period with scheduled Follow-up Visits (Monthly Follow-u...


Agents Found By Disease-Level Search

Searched directly from “Atrial Fibrillation” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 9-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

40 agents shown (approved or with trial evidence) — 37 not found by the gene-target search above.

DabigatranNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03996772 NCT01994265

RivaroxabanNOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03996772 NCT02273700

Oral anticoagulantNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04099238 NCT04233515

BWLT+CRNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05600829

CR-OnlyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05600829

bucindolol hydrochloride

· 1 trial · source: ClinicalTrials.gov
NCT01970501

metoprolol succinate

· 1 trial · source: ClinicalTrials.gov
NCT01970501

Apixaban Oral TabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03996772

Edoxaban TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03996772

12-Lead ECGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03492554

ECG-I Mapping of Atrial FibrillationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04633265

EdoxabanNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05732506

Adaptive Servo-VentilationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00263757

continue warfarin through the procedureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00721136

Hold warfarinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00721136

Warfarin held with heparin transition.NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00721136

PVI aloneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05989321

IvabradineNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT03987204

EthanolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01898221

Hybrid procedureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03428048

left atrial appendage occlusionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03428048

Aggressive Risk Factor ControlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03186976

Ambulatory ECGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03769207

DiagnosticNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00279981

Standard escalating shocksNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02923414

High energy shock protocolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02923414

Antiarrhythmic Drug TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00340314

Study WatchNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04074434

optimizer smartNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05550792

Termination of AFNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02238392

WarfarinNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01994265

Antiarrhythmic drugNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00116428

ICE Image guidanceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04950192

14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03221777

Bisoprolol

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02391337

DigoxinNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02391337

Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02619396

Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02619396

Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02619396

Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wallNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02619396

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.